Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Licenses Technology to Predict EGFR Inhibitor Response

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Transgenomic today announced it has acquired an exclusive worldwide license to biomarkers for predicting patient response to EGFR inhibitors.

The biomarkers were discovered by researchers at New York's Montefiore Medical Center and are described in its patent application titled, "Method for determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab, and erlotinib." The invention relates to tumor-specific mutations in the genes PIK3CA and PTEN that can be useful in predicting patient non-response to EGFR inhibitors.

Transgenomic said that it is incorporating the PIK3CA and PTEN gene assays into its menu of cancer profiling tests available through its clinical reference laboratories. It is also developing test kits for sale to other labs. The company is offering testing of the genes to pharmaceutical firms to support their drug development work.

Craig Tuttle, CEO of Transgenomic, called the agreement "integral to the continued development of our leadership position in oncology. … Our exclusive access to this new intellectual property will enable us to provide the most comprehensive analysis for predicting response to cancer treatment in the current market."